Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy

Digestive and Liver Disease

Volumn 41, Issue 4, 2009, Pages 303-307

  Belfiori, B ^a   Ciliegi, P ^b   Chiodera, A ^c   Bacosi, D ^c   Tosti, A ^a   Baldelli, F ^a   Francisci, D ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Addiction Service   (Italy)

^c Clinical Department of Infectious Diseases   (Italy)

Author keywords

Buprenorphine; Hepatitis C treatment; Intravenous drug user; Methadone; Peginterferon

Indexed keywords

BUPRENORPHINE; LEVOTHYROXINE; METHADONE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; ITALY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OBSERVATIONAL STUDY; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; THYROIDITIS; VIRUS LOAD; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BUPRENORPHINE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; METHADONE; MIDDLE AGED; NARCOTICS; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECURRENCE; RIBAVIRIN; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62049084632     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.08.009     Document Type: Article

References (23)

1. Backmund M., Reimer J., Meyer K., Gerlach J.T., and Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis 40 (2005) S330-S335
2. Edling B.R., Kresina T.F., Raymond D.B., Carden M.R., Gourevitch M.N., Rich J.D., et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 40 (2005) S276-S285
3. Dore G.J., Freeman A.J., Law M., and Kaldor J.M. Is severe liver disease a common outcome for people with chronic hepatitis C?. J Gastroenterol Hepatol 17 (2002) 423-430
4. Seef L.B. Natural history of chronic hepatitis C. Hepatology 36 (2002) S35-46
5. Golub E.T., Latka M., Hagan H., Havens J.R., Hudson S.M., Kapadia S., et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck depression inventory. J Urban Health 81 (2004) 278-290
6. Schaefer M., Heinz A., and Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction 99 (2004) 1167-1175
7. Backmund M., Meyer K., Von Zielonka M., and Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 34 (2001) 188-193
8. Sylvestre D.L. Treating hepatitis C in metadone maintenance patients: an interim analysis. Drug Alcohol Depend 67 (2002) 117-123
9. Verrando R., Robaeys G., Mathei C., and Buntinx F. Metadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Gastroenterol Belg 68 (2005) 81-85
10. National Institute of Health (NIH). Consensus Development Conference Statement. Management of Hepatitis C. Hepatology 36 (2002) 3-20
11. Strader D.B., Wright T., Thomas D.L., and Seef L.B. AASLD practice guideline: diagnosis, management and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
12. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alpha 2b-plus ribavirin compared with interferon alpha 2b-plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
13. Mauss S., Berger F., Goelz J., Jacob B., and Schmutz G. A prospective controlled study of Interferon-based therapy of chronic hepatitis C in patients on metadone maintenance. Hepatology 40 (2004) 120-124
14. Guadagnino V., Trotta M.P., Montesano F., Babudieri S., Caroleo B., Armignacco O., et al., for the Nocchiero Study Group. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 102 (2007) 423-431
15. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
16. European Monitoring Centre for Drugs and Drug Addiction (E.M.C.D.D.A.), ; 2006 [accessed 25.06.07].
17. European Monitoring Centre for Drugs and Drug Addiction (E.M.C.D.D.A.), ; 2006 [accessed 25.06.07].
18. Garfein R.S., Doherty M.C., Monterroso E.R., Thomas D.L., Nelson K.E., and Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 18 Suppl. 1 (1998) 11-19
19. Bruno S., Camma C., Di Marco V., Rumi M., Vinci M., Camozzi M., et al. Peginterferon alpha 2-b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 41 (2004) 474-481
20. Laine C., Hauck W.W., Gourevitch M.N., Rothman J., Cohen A., and Turner B.J. Regular outpatient medical and drug abuse care and subsequent hospitalization of person who use illicit drugs. J Am Med Assoc 285 (2001) 2355-2362
21. Weisner C., Mertens J., Parthasarathy S., Moore C., and Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. J Am Med Assoc 286 (2001) 1715-1723
22. Sylvestre D.L. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 40 (2005) S321-S324
23. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N., et al. Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology 37 (2003) 443-451